NK-cell activity in immunotoxicity drug evaluation

Karin Cederbrant1, Maritha Marcusson-Ståhl, Fabienne Condevaux

  • 1Department of Molecular Toxicology/Immunotoxicology, Safety Assessment, AstraZeneca R&D Södertälje, SE-151 85, Södertälje, Sweden. karin.cederbrant@astrazeneca.com

Toxicology
|February 13, 2003
PubMed